Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 8
2003 7
2004 7
2005 11
2006 2
2007 8
2008 9
2009 13
2010 8
2011 9
2012 7
2013 15
2014 14
2015 12
2016 12
2017 8
2018 14
2019 7
2020 20
2021 19
2022 16
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

218 results

Results by year

Filters applied: . Clear all
Page 1
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.
Luke JJ, Davar D, Andtbacka RH, Bhardwaj N, Brody JD, Chesney J, Coffin R, de Baere T, de Gruijl TD, Fury M, Goldmacher G, Harrington KJ, Kaufman H, Kelly CM, Khilnani AD, Liu K, Loi S, Long GV, Melero I, Middleton M, Neyns B, Pinato DJ, Sheth RA, Solomon SB, Szapary P, Marabelle A. Luke JJ, et al. Among authors: bhardwaj n. J Immunother Cancer. 2024 Apr 18;12(4):e008378. doi: 10.1136/jitc-2023-008378. J Immunother Cancer. 2024. PMID: 38641350 Free PMC article.
Structural basis for self-discrimination by neoantigen-specific TCRs.
Finnigan JP, Newman JH, Patskovsky Y, Patskovska L, Ishizuka AS, Lynn GM, Seder RA, Krogsgaard M, Bhardwaj N. Finnigan JP, et al. Among authors: bhardwaj n. Nat Commun. 2024 Mar 8;15(1):2140. doi: 10.1038/s41467-024-46367-9. Nat Commun. 2024. PMID: 38459027 Free PMC article.
Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Galsky MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, Chan KG, Lewis S, Achkar BE, Dorff TB, Cetnar JP, Neil BO, D'Souza A, Mamtani R, Kyriakopoulos C, Jun T, Gogerly-Moragoda M, Brody R, Xie H, Nie K, Kelly G, Horowitz A, Kinoshita Y, Ellis E, Nose Y, Ioannou G, Cabal R, Del Valle DM, Haines GK, Wang L, Mouw KW, Samstein RM, Mehrazin R, Bhardwaj N, Yu M, Zhao Q, Kim-Schulze S, Sebra R, Zhu J, Gnjatic S, Sfakianos J, Pal SK. Galsky MD, et al. Among authors: bhardwaj n. Nat Med. 2024 Apr;30(4):1211. doi: 10.1038/s41591-024-02814-0. Nat Med. 2024. PMID: 38242983 Free PMC article. No abstract available.
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Galsky MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, Chan KG, Lewis S, Achkar BE, Dorff TB, Cetnar JP, Neil BO, D'Souza A, Mamtani R, Kyriakopoulos C, Jun T, Gogerly-Moragoda M, Brody R, Xie H, Nie K, Kelly G, Horowitz A, Kinoshita Y, Ellis E, Nose Y, Ioannou G, Cabal R, Del Valle DM, Haines GK, Wang L, Mouw KW, Samstein RM, Mehrazin R, Bhardwaj N, Yu M, Zhao Q, Kim-Schulze S, Sebra R, Zhu J, Gnjatic S, Sfakianos J, Pal SK. Galsky MD, et al. Among authors: bhardwaj n. Nat Med. 2023 Nov;29(11):2825-2834. doi: 10.1038/s41591-023-02568-1. Epub 2023 Oct 2. Nat Med. 2023. PMID: 37783966 Free PMC article. Clinical Trial.
Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer.
Anker J, Pal SK, Kim-Schulze S, Wang H, Halperin R, Uzilov A, Imai N, Eikawa S, Saito T, Sebra R, Hahn NM, Patel M, Qi J, Xie H, Bhardwaj N, Gnjatic S, Galsky MD. Anker J, et al. Among authors: bhardwaj n. J Immunother Cancer. 2023 Aug;11(8):e007613. doi: 10.1136/jitc-2023-007613. J Immunother Cancer. 2023. PMID: 37607770 Free PMC article.
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.
Gregucci F, Spada S, Barcellos-Hoff MH, Bhardwaj N, Chan Wah Hak C, Fiorentino A, Guha C, Guzman ML, Harrington K, Herrera FG, Honeychurch J, Hong T, Iturri L, Jaffee E, Karam SD, Knott SRV, Koumenis C, Lyden D, Marciscano AE, Melcher A, Mondini M, Mondino A, Morris ZS, Pitroda S, Quezada SA, Santambrogio L, Shiao S, Stagg J, Telarovic I, Timmerman R, Vozenin MC, Weichselbaum R, Welsh J, Wilkins A, Xu C, Zappasodi R, Zou W, Bobard A, Demaria S, Galluzzi L, Deutsch E, Formenti SC. Gregucci F, et al. Among authors: bhardwaj n. Oncoimmunology. 2023 Jun 21;12(1):2222560. doi: 10.1080/2162402X.2023.2222560. eCollection 2023. Oncoimmunology. 2023. PMID: 37363104 Free PMC article. Review.
Cancer immunity derailed: PGE2 misconducts cDC1s.
Brown M, Tran MA, Bhardwaj N. Brown M, et al. Among authors: bhardwaj n. Immunity. 2023 Jun 13;56(6):1165-1167. doi: 10.1016/j.immuni.2023.05.015. Immunity. 2023. PMID: 37315532
TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer.
Park MD, Reyes-Torres I, LeBerichel J, Hamon P, LaMarche NM, Hegde S, Belabed M, Troncoso L, Grout JA, Magen A, Humblin E, Nair A, Molgora M, Hou J, Newman JH, Farkas AM, Leader AM, Dawson T, D'Souza D, Hamel S, Sanchez-Paulete AR, Maier B, Bhardwaj N, Martin JC, Kamphorst AO, Kenigsberg E, Casanova-Acebes M, Horowitz A, Brown BD, De Andrade LF, Colonna M, Marron TU, Merad M. Park MD, et al. Among authors: bhardwaj n. Nat Immunol. 2023 May;24(5):792-801. doi: 10.1038/s41590-023-01475-4. Epub 2023 Apr 20. Nat Immunol. 2023. PMID: 37081148
218 results